Hello Avatar! Welcome to the BowtiedBiotech podcast, where science meets business! If you're fascinated by breakthrough biotech, bold innovations, and the business behind the science, you're in the right place. Each week, we dive into the world of biotech with fresh insights, sharp analysis, and the stories that are shaping the future of health. Whether you’re an industry insider, an investor, or just biotech-curious, we’ve got something for you.
We are now publishing 7x per week according to the following cadence:
Mondays: Stock Analysis & Biotech Catalysts
Tuesdays: Biotech hot topics (X-article)
Wednesdays: Podcast
Thursdays: Public & Private Biotech Markets
Fridays: Your Weekly Biotech Fix
Saturdays: Podcast
Sundays: Biotech Strategic Topics
We are also publishing unique content on X - be sure to follow up if you are not already @BowTiedBiotech. And to check-out the archive of our work on X you can find it on our website at: BowtiedBiotech.subtack.com/x-articles.
SUBSCRIBE TO PODCAST HERE:
Please help spread the work by subscribing and hitting the share button if you are enjoying content!
Welcome to the Bowtied Biotech Podcast, where science meets strategy and innovation drives investment. This week, we're diving into one of the most anticipated events of the year: the 2025 J.P. Morgan Healthcare Conference. Known as the biopharma industry’s “Super Bowl,” this gathering of innovators, investors, and executives sets the stage for key announcements, deal-making, and glimpses into the future of healthcare. From gene editing breakthroughs and AI-driven diagnostics to licensing deals reshaping risk and emerging trends in drug development, we'll dissect what’s at stake and what’s next. Join us as we navigate the catalysts, controversies, and opportunities shaping the biotech landscape in 2025.
📣🎙️ TODAY’S PODCAST:
[ 0:00 ] Intro
[ 0:52 ] JPM Preview
[ 2:28 ] AI in Biopharma
[ 3:15 ] Licensing Deals vs. M&A
[ 4:02 ] Galapagos Restructures
[ 4:43 ] Layoffs in Biopharma
[ 5:26 ] Political Uncertainty
[ 5:53 ] Rise of Mega Financing Rounds
[ 6:33 ] Maze Therapeutics IPO
[ 6:55 ] Orna Therapeutics
[ 7:46 ] The Obesity Drug Race
[ 10:11 ] CRISPR and Beyond
[ 10:52 ] Windward Bio
[ 12:00 ] Venture Capital’s Role in Biotech
[ 13:55 ] Final Thoughts on Biopharma in 2025
[ 16:51 ] Closing Remarks
CONCLUSION
We hope you are enjoying our first leap into the podcast world! Instead of waiting until everything is perfect, we’re diving in and will continue improving as we go. Feel free to send us your suggestions, feedback, or constructive criticism—we’d love to hear from you!
As a reminder, if looking to go deeper into the topics we cover check out our website BowTiedBiotech.com, or DM us on twitter, or email us: bowtiedbiotech@gmail.com
ABOUT BOWTIEDBIOTECH
As a reminder, the purpose of the BowTiedBiotech substack is two-fold. Primarily, we aim to provide our scientist audience the tools to build a biotech company and ultimately translate their ideas into medicines for patients. Secondarily, biotech investors may find this substack useful as we will be providing weekly market updates of the public AND private markets as well as heavily leveraging current financing events as teaching examples.
DISCLAIMER
None of this is to be deemed legal or financial advice of any kind. All updates are sourced from publicly available disclosures. Insights are *opinions* written by an anonymous cartoon/scientist/investor.
TOP BOWTIEDBIOTECH NEWSLETTERS
Share this post